Data confirms effectiveness of NanoActive technology
NanGenex increases water solubility of nanoformulations of drugs
NanGenex of Budapest, Hungary, has completed first round in vivo testing of NanoActive nanoformulations of blockbuster drugs.
Using its proprietary NanoActive continuous flow technology, NanGenex has been able to increase the water solubility of three such widely used drug compounds. Laboratory tests showed a 10 to 1,000-fold increase in water solubility for the different compounds. Furthermore, the redispersibility and dissolution of the compounds in a biological relevant medium was practically instantaneous, the firm said.
NanGenex carried out animal studies on Sprague-Dawley rats and beagle dogs in order to assess whether improvement in solubility and dissolution rate results in increased oral absorption and bioavailability.
For all three compounds there was a significant (2 to 7-fold) increase in bioavailability after oral administration of the NanoActive formulation compared with administration of the reference compound via the same route.
Blood concentrations were also detected earlier following administration (30–45 minutes for the NanoActive formulations, 120 minutes for the reference compounds) indicating faster oral absorption of the NanoActive formulations.
Using the new formulations the same therapeutic blood concentrations can be achieved by administering significantly lower drug doses. Furthermore, instantaneous release of the drug from the formulation could result in faster onset of action for compounds where dissolution is the rate-limiting step of oral absorption.
